Should you buy Anavex Life Sciences stock now?
The technical signal for Anavex Life Sciences is currently NEUTRAL. Anavex Life Sciences trades at $3.25 as of 8/6/2026. The overall technical signal is: Hold. The technical analysis shows the following: MACD is positive (bullish trend) at 0.100 with rising momentum (signal: 0.012); RSI is at 70.3 (overbought), suggesting the price may have risen too quickly; the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $20.00 points to 516.3% upside. This is a technical observation based on current data, not investment advice.
What is the price target for Anavex Life Sciences stock?
The average analyst price target for Anavex Life Sciences is $20.00. The current price is $3.25, which gives an upside of 516.3%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $18.00 and $22.00.
Is Anavex Life Sciences a dividend stock?
No, Anavex Life Sciences does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Anavex Life Sciences stock?
Anavex Life Sciences is rated as a stock with extreme risk. the annual standard deviation is 86.5%, which classifies the stock as extreme risk. In addition, an RSI of 70.3 signals overbought (elevated risk of a pullback).
Is Anavex Life Sciences overvalued?
No, Anavex Life Sciences is considered undervalued based on the analyst price target (516.3% upside). Anavex Life Sciences has the following valuation ratios: a P/B ratio of 2.1. The analyst price target suggests that the stock is undervalued by 516.3%.
Is Anavex Life Sciences overbought?
Yes, Anavex Life Sciences is overbought with an RSI of 70.3 (above 70). The technical indicators show: RSI is at 70.3 (above the 70 mark), which signals the price is overbought and may have risen too quickly. In addition, the price is 25.0% above the 20-day average (short-term uptrend). In addition, MACD is positive with rising momentum (bullish).
When is the next Anavex Life Sciences earnings report?
Anavex Life Sciences reports its next earnings on August 11, 2026. The stock currently trades at $3.25. The RSI is at 70.3, so the report can reinforce the current technical trend.
Is Anavex Life Sciences shorted?
Yes, Anavex Life Sciences is shorted with 15.9% of the free float sold short. This is a very high level of short selling, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains. Data is updated daily based on official filings with the SEC.
Are insiders buying Anavex Life Sciences stock?
No, insiders are not buying Anavex Life Sciences shares – they are net sellers. Across the last 20 reported transactions, the split is 8 purchases and 12 sales, with a net 15,034,214 $ sold. Active sellers include MISSLING CHRISTOPHER U, Thomas Steffen, Christopher U Missling and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Anavex Life Sciences a good stock?
Based on our total score, Anavex Life Sciences is rated as a disastrous stock with a total score of 10 out of 100. The stock scores very low on value, quality and momentum – it is among the worst in our database. The score is made up of Value: 15/100, Quality: 9/100, Momentum: 5/100. In addition: analysts see 516.3% upside to the price target; technical signal: Hold. Whether Anavex Life Sciences is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Anavex Life Sciences stock?
The outlook for Anavex Life Sciences based on current data: the average analyst price target is $20.00 (+516.3%); the next earnings report is due on 8/11/2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Anavex Life Sciences stock rising?
Anavex Life Sciences is rising right now. The technical indicators show: the price is 25.0% above the 20-day average; MACD is positive with rising momentum (bullish signal); short interest is 15.9% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Anavex Life Sciences go?
The average analyst price target for Anavex Life Sciences is $20.00, which corresponds to a potential gain of 516.3% from the current price of $3.25. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Anavex Life Sciences fall?
We lack enough history to give a specific floor for Anavex Life Sciences. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Anavex Life Sciences do?
Anavex Life Sciences Corp. er et biofarmaceutisk firma, der udvikler medicin mod sygdomme i centralnervesystemet. De fokuserer især på neurodegenerative lidelser.
Deres mest kendte middel er ANAVEX 2-73, som de tester mod både Alzheimers og Parkinsons. Anavex Life Sciences ar... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Anavex Life Sciences as an investment.
Did Anavex Life Sciences raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Anavex Life Sciences. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Anavex Life Sciences making money or losing money?
We have no current profitability data for Anavex Life Sciences. See the latest report in the earnings history above.
Can Anavex Life Sciences go bankrupt?
The bankruptcy risk of Anavex Life Sciences is rated as low. Altman Z2 (a model for assessing financial distress) is 11.13 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 1 — which is weak. Debt relative to equity is 13% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Anavex Life Sciences have a lot of debt?
No, Anavex Life Sciences has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 13%. For the sundhed sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
